DrugRisk Alerts of Court Update Showing Monthly Rise In Byetta Lawsuits

The Drug Risk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
byetta lawsuit
Anyone affected by cancer after taking Byetta is encouraged to visit the DrugRisk center or speak with a lawyer about their legal options.

Dallas, TX (PRWEB) October 24, 2013

The DrugRisk.com diabetes medication safety center is announcing updated information for patients taking the medication Byetta. Court records released this week show the number of lawsuits alleging the drug caused cancer have more than doubled in the past month*.

DrugRisk is a free resource for those taking popular prescription drugs. By providing patients with the latest product recalls, safety alerts, research and litigation news, they can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.

Byetta is a popular injectable medication prescribed to those with type-II diabetes to lower blood sugar levels. However, the resource center has added information showing experts disagree about its safety.

In 2011, a study from UCLA suggested subjects given Byetta may have higher occurrences of pancreatic cancer and thyroid cancer**. This year, the Journal for the American Medical Association also advised that drugs like Byetta can double the risk of pancreatitis, a major risk factor for pancreatic cancer***.

The Institute for Safe Medication Practices has attributed a majority of serious diabetes drug side effect reports to the FDA to Byetta****. However, the FDA has not issued a recall or required new label warnings.

Due to the growing number of patients who have filed a Byetta lawsuit alleging cancer, cases were consolidated to a special multidistrict litigation federal court. (In Re: Incretin-Based Therapies Products Liability Litigation, MDL 2452, Southern District of California).

Now, court records released this week show the number of cases filed over incretin-class medications like Byetta, Januvia, Janumet or Victoza has more than doubled in a month, from 60 on September 11 to 150 on October 17*.

Anyone affected by cancer after taking Byetta is encouraged to visit the DrugRisk center or speak with a lawyer about their legal options. However, DrugRisk only recommends lawyers who have already handled these complex Byetta lawsuits.

For more information on the research, side effects and litigation news related to Byetta and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*JPML 10/17/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-October-17-2013.pdf
**Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
***JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
****ISMP QuarterWatch April, 2013.ismp.org/QuarterWatch/pdfs/2012Q3.pdf


Contact